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Abstract
Background: Gene ablation studies have revealed that tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL, Apo2L, TNFSF10) plays a crucial role in tumor surveillance, as TRAIL-deficient mice exhibit an increased
sensitivity to different types of tumorigenesis. In contrast, possible tumor-protective effect of increased levels of
endogenous TRAIL expression in vivo has not been assessed yet. Such models will provide important information
about the efficacy of TRAIL-based therapies and potential toxicity in specific tissues.
Methods: To this aim, we engineered transgenic mice selectively expressing TRAIL in the skin and subjected these
mice to a two-step chemical carcinogenesis protocol that generated benign and preneoplastic lesions. We were
therefore able to study the effect of increased TRAIL expression at the early steps of skin tumorigenesis.
Results: Our results showed a delay of tumor appearance in TRAIL expressing mice compared to their wild-type
littermates. More importantly, the number of tumors observed in transgenic animals was significantly lower than in
the control animals, and the lesions observed were mostly benign. Interestingly, Wnt/b-catenin signaling differed
between tumors of wild-type and TRAIL transgenics.
Conclusion: Altogether, these data reveal that, at least in this model, TRAIL is able on its own to act on pre-
transformed cells, and reduce their tumorigenic potential.
Background
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL, Apo2L, TNFSF10), a type II trans-membrane
death ligand, has the unique property of inducing apop-
tosis in tumor cells while sparing normal ones [1]. The
human protein shares 65% amino-acids identity with its
murine counterpart [2]. TRAIL forms homotrimers that
ligate to two types of receptors: death receptors that
trigger TRAIL-induced apoptosis and decoy receptors
that can antagonize apoptosis induction. In humans, two
death receptors (DR4/TRAIL-R1/TNFRSF10A and DR5/
TRAIL-R2/TNFRSF10B) [3,4] and two decoy receptors
(DcR1/TRAIL-R3/TNFRSF10C and DcR2/TRAIL-R4/
TNFRSF10D) [5] have been identified. In mice two
decoy receptors (mDcR1 and mDcR2) have been charac-
terized [6] but only one death-inducing receptor (mDR5,
mTRAILR2) that shares sequence homology with both
human DR4 and DR5 was found [7].
Binding of TRAIL to one of the death receptors
results in receptor oligomerization and recruitment of
the FAS-associated protein with death domain (FADD),
which itself recruits membrane proximal caspases (cas-
pase 8 and 10). The resulting protein complex has auto-
catalytic activity and is designated as the death-inducing
signaling complex (DISC). The activation of this com-
plex induces activation of a caspase cascade, which
cleaves numerous proteins and ultimately leads to cell
death [[8] and references therein].
Increasing evidence from various types of experimen-
tal models supports the notion that TRAIL can affect
tumor onset and development. Indeed, tumor transplan-
tation experiments with TRAIL- and TRAILR-deficient
mice and the use of TRAIL-neutralizing antibodies
revealed that endogenous TRAIL expressed in NK cells
contributes to host immunosurveillance against primary
tumors and metastases. Moreover, TRAIL exerts a
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vivo, causing negligible effects on normal cells when
exogenously administered, an important feature of this
cascade regarding its therapeutic potential [9-25]. There-
f o r e ,r e c o m b i n a n tT R A I L ,T R A I L“mimics” [26] and
agonistic TRAIL receptor antibodies are attractive
potential tools for anticancer therapy.
While loss-of-function studies have provided impor-
tant information revealing accelerated tumor formation
in TRAIL-deficient mice and thereby confirmed its
implication in tumor defense, the corresponding in vivo
gain-of-function analysis demonstrating protection
against tumorigenesis by increasing endogenous TRAIL
levels in the animal or a given tissue has not yet been
done. Irrespective of the information that can be
obtained with recombinant TRAIL, which corresponds
only to a part of TNFSF10, TRAIL mimics or with ago-
nistic TRAIL receptor antibodies, an understanding of
the impact of increasing cellular TRAIL levels is an
essential aspect of its biological function. Moreover,
with this approach, cell and tumor-type efficacies
including possible adverse effects of TRAIL therapies
can be assessed, as well as the toxicity of increased
levels of endogenous TRAIL in vivo, including effects on
early development. Note that not only tumoricidal, but
also increased proliferation upon exposure to recombi-
nant TRAIL has been reported in some cases of human
cancer [27] and inflammation models [28]. Finally, only
in vivo models in which TRAIL is overexpressed in
selected tissues will reveal at which stage of tumor
development TRAIL overexpression becomes tumor-
protective or tumoricidal, and which cell types (prema-
lignant or malignant cells, tumor proximal normal cells,
cells of the immune system) contribute. To this aim we
have initiated a study in which the effect of TRAIL over-
expression in the skin on chemically induced epithelial
tumorigenesis was assessed.
For this we took advantage of the well-established
7,12-dimethyl-benz-anthracene/12-0-tetradecanoylphor-
bol-13-acetate (DMBA/TPA) two-stage skin carcinogen-
esis model. This tumor induction protocol recapitulates
comprehensively the multistage nature of human epithe-
lial cancer development [29], as it first gives rise to
benign neoplastic lesions (papillomas) from which a
small percentage progress into malignant squamous cell
carcinomas (SCCs). In most strains of mice however,
progression of benign papillomas into SCCs is a rare
and late event. Ultimately, a small fraction of these
tumors can metastasize to distant organs. To study the
protective effect of increased endogenous TRAIL levels
we engineered mice to specifically overexpress TRAIL in
the skin and subjected these mice to the two-step che-
mical carcinogenesis protocol.
Methods
Generation of transgenic mice
To selectively induce expression of TRAIL in the skin, a
construct was generated in which the mouse TRAIL
cDNA was placed under the control of the human kera-
tin 14 (K14) promoter. To allow a more efficient expres-
sion of the transgene, an intron of the b-globin gene,
flanked on both sides by small parts of the exons 1 and
2, respectively, was introduced between the K14 promo-
ter and the mTRAIL cDNA. The SV40 3’UTR was
added at the end of the construct. This construct was
microinjected into the male pronucleus of a fertilized
mouse oocyte, which was than transplanted into a
pseudo-pregnant recipient female.
Carcinogenesis
The mice were housed in a temperature-controlled
r o o mw i t h1 2hc y c l e so fl i g h ta n dd a r k .8t o1 0w e e k s
old wild type and TRAIL transgenic mice were shaved
to synchronize the hair cycle and treated the day after
w i t has i n g l ed o s eo f5 0μg DMBA (7,12-dimethyl-ben-
zanthracene) (Sigma, St Louis, MO, USA) in 100 μl
acetone. One week after DMBA application, 5 μgT P A
(12-O-tetradecanoyl-phorbol-13 acetate) (Sigma) in
200 μl acetone was applied topically twice a week for
35 weeks. Control mice received acetone only. The
number of tumors per mouse was weekly recorded and
their size was measured with a Vernier calliper.
In situ Hybridization
Skin samples from wild-type and TRAIL transgenic mice
were collected, fixed overnight in 4% formaldehyde and
embedded into paraffin. The paraffin sections were first
rehydrated and primed with proteinase K, followed by
dehydratation through graded ethanols. Pre-treated sec-
tions were covered with 150 μl hybridization buffer
(50% formamide, 10% dextran sulfate, 1 × Denhart’s
solution, 10 mM Tris-HCl pH 7.5, 600 mM NaCl,
1 mM EDTA, 0.25% SDS, 0.5 mg/ml yeast tRNA) con-
taining 100 ng/ml of DIG-labeled RNA probe, and
hybridized at 55°C overnight. After hybridization, slides
were washed twice with 2 × SSC, followed by 0.2 × SSC
once at 45°C to remove unbound probe. The sections
were then incubated with Blocking buffer (0.1 M Tris-
HCl pH 7.5, 0.15 M NaCl, saturated with block reagent)
for 1 h at room temperature. Alkaline phosphatase-
conjugated anti-DIG antibody was diluted in blocking
buffer and incubated on slides for 2 h at room tempera-
ture. Sections were then rinsed three times with detec-
tion buffer (0.1 M Tris-HCl pH 9.5, 0.1 M NaCl, 50
mM MgCl2), and then covered with detection buffer
containing 0.18 mg/ml BCIP and 0.34 mg/ml NBT. The
chromogenic reaction was carried out at 4°C for 16 h.
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with coverslips and photographed.
In order to synthesize the RNA probe, the 3’ UTR of
the construct introduced in mice was subcloned using
the following primers:
5’ACTGACGAATTCCCCGGGGGATCCAGATCT
TATT3’ and
5’ ACTGACCTCGAGCCAGACATGATAAGATA
CATTGATGAG 3’
Semi-quantitative PCR
Skin samples from wild type and TRAIL transgenic mice
were placed in 1 ml TriZol and homogenized using an
TissueRuptor. RNA was extracted according to the man-
ufacturer’s protocol. A DNase treatment was performed,
followed by reverse transcription. The cDNAs obtained
were analyzed by PCR, using the following primers, 5’
GATCCTGAGAACTTCAGG 3’ and 5’ CTGCTTC
ATCTCGTTGGTGA 3’, which are specific for the
transgene.
Immunoblotting
Skin samples from wild type and TRAIL transgenic mice
were disrupted in liquid nitrogen using a pestle and a
mortar. The resulting powder was homogenized in RIPA
buffer (1% NP 40, 0.5% Sodium-deoxycholate, 0.1% SDS
in PBS) containing proetase inhibitors. Western blotting
was performed according to standard protocols. Anti-
TRAIL (R&D systems), anti-phospho-GSK3b (Ser9)
(Cell signaling), anti-bcatenin (Upstate) and anti-Actin
(Santa Cruz) antibodies were used. Secondary reagent
used was horseradish peroxidase-coupled donkey anti-
goat, goat anti-rabbit or goat anti-mouse antibodies
(Santa Cruz).
Histological analysis
Tumors were excised 35 weeks after DMBA/TPA appli-
cation, fixed in 4% formaldehyde and embedded in par-
affin. Sections of 5 μmw e r em a d eu s i n gam i c r o t o m e
and stained with hematoxilin and eosin according to
standard protocols. Pictures were taken using a Leica
microscope.
Immunofluorescence
Cryosections of lesions were rehydrated in PBS and
fixed for 5 min at room temperature in 4% paraformal-
dehyde. After two washes in PBS 1X, tween 20 0.1%, the
sections were saturated for 1 h in Normal Goat Serum
(NGS) 5%, PBS 1X, tween 20 0.1% at room temperature
and then incubated with primary antibodies overnight at
4°C. Keratin 1 antibody (Covance Dabco) was diluted at
1/500
e and a6-integrin antibody (BD Pharmingen) was
diluted at 1/200
e. Sections were than incubated for 1 h
at room temperature with alexa 488 conjugated Donkey
anti-Rabbit and Cy3 conjugated Donkey anti-Rat antibo-
dies diluted at 1/400
e, washed and counterstained with
Hoechst.
Immunohistochemistry
Paraffin sections of skin were deparaffinated in histosol
and rehydrated. Antigen retrieval was performed in
10 mM sodium citrate pH 6.0 at 95°C for 10 min. Endo-
genous peroxidase activity was blocked by incubation in
1% H2O2 for 5 min. After 1 H of blocking, the sections
were incubated over-night at 4°C with Ki67 antibody
(1:1000; Tebu-Bio), in humidified chamber. The slides
were then washed and incubated with biotin-linked sec-
ondary antibody, followed by the ABC elite reagent (Vec-
tor). The AEC reagent (Vector) was used as a substrate
prior to counterstaining with hematoxilin and mounting.
Results
Given the potential ability of TRAIL to induce apoptosis
of tumor cells, while sparing normal cells, we decided to
assess whether specific TRAIL expression in the skin
could prevent tumor formation following a chemical
carcinogenesis. To accomplish this, we engineered mice
expressing mouse TRAIL cDNA under the control of
the human keratin 14 promoter (Figure 1A). It has been
previously established that such constructs express the
transgene specifically in the basal cell layer of the epi-
dermis [30,31]. One mouse line was obtained in the
C57BL/6 background, and tested for TRAIL expression
Figure 1 TRAIL expression in the skin driven by the human
keratin 14 promoter. (A) Diagram of the construct introduced into
ES cells. Between the mouse TRAIL cDNA and the human keratin 14
promoter, one b-globin intron and small parts of exon 1 and exon
2 were placed. The 3’UTR of SV40 was added at the end the TRAIL
cDNA. The primers used for RNA expression analysis and the probe
used for in situ hybridization are indicated on the scheme. (B) RNA
was extracted from skin of wild type and transgenic animals and
after reverse-transcription, semi-quantitative PCR was performed
using primers specific for the transgene. 36B4 was used as a
positive control. (C) RNA expression was also evaluated by in situ
hybridization, using a probe specific for the transgene. Blue staining
shows TRAIL expression in the basal cell layer of epidermis of
transgenic animals. Bar, 100 μm. (D) Western blot analysis of protein
extracts from wild-type and transgenic mice using an anti-TRAIL
antibody and actin antibody as a loading control.
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mately 5-fold higher TRAIL expression was found in the
skin of transgenic animals than in wild-type animals
(Figure 1B and 1D). Moreover, in situ hybridization
using a probe specific for the transgene confirmed the
restricted expression of the transgene in the basal cell
layer of the epidermis (Figure 1C). These mice were
thus considered valid to test the effect of TRAIL overex-
pression on chemical carcinogenesis relative to their
non-transgenic littermates.
In order to compare the tumor development in wild-type
and TRAIL-expressing mice, we proceeded to a DMBA/
TPA two-stage chemical carcinogenesis protocol, which
consists of a single application of DMBA, followed by mul-
tiple applications of TPA for a 35 weeks period of time.
While DMBA application corresponds to the initiation step
of the tumor development process by inducing activating
mutations of Ha-Ras oncogene [32,33], TPA application
corresponds to the promotion step by inducing a clonal
expansion of the initiated cells to form a benign tumor [34],
which can eventually progress to a malignant carcinoma.
We first examined the skin structure of wild type and
transgenic mice after a short-term treatment of DMBA/
TPA, corresponding to a single application of DMBA fol-
lowed by four applications of TPA. The epidermal thick-
ening normally observed in wild-type animals after TPA
treatment was not affected in TRAIL expressing mice
(Figure 2A and 2B), suggesting that TRAIL expression
does not impair the proliferation rate induced by TPA
application. Ki67 staining of skin sections from treated
wild type and transgenic mice further confirmed this
notion (Figure 2C). We then started the full DMBA/TPA
treatment (as illustrated in Figure 3A) on cohorts of 21
wild type and 21 transgenic mice. Whereas control ani-
mals started to develop lesions after 8 weeks of treat-
ment, the onset of lesion formation was shortly delayed
in TRAIL expressing mice, with the first appearance after
11 weeks (Figure 3B). Apart from that difference, the
general tumor incidence rate was not significantly
affected in TRAIL expressing mice compared to control
mice, as independently of the genotype, approximately
90% of the animals developed lesions before the 30
th
week of the treatment (Figure 3B). However, the most
striking difference concerned the number of lesions
observed in TRAIL expressing mice compared to control
mice. Indeed, whereas the cumulative number of lesions
in control animals was around 50, it was only about 30 in
T R A I Lt r a n s g e n i cm i c ea tt h ee n do ft h ee x p e r i m e n t
(Figure 3C). When analyzing the number of lesions per
animal, we noticed that whereas transgenic mice never
presented more then three lesions, wild-type mice could
display up to six lesions (Figure 3D). However, the size of
the lesions was not significantly different in the wild type
compared to transgenic animals (data not shown).
At the end of the treatment, the lesions were excised
for histological analysis. Surprisingly, none of the lesions
Figure 2 TRAIL expression does not affect the proliferation
rate induced by a short DMBA/TPA treatment. Groups of four
control and TRAIL transgenic animals were treated with DMBA/TPA
for three weeks (one DMBA and four TPA applications). (A) Analysis
of cell proliferation on histological skin sections with hematoxilin &
eosin staining. Bar, 50 μm. (B) Quantification of epidermal thickness
in micrometers, evaluated by measurements of 15 fields per animal.
(C) Cell proliferation evaluated by Ki67 staining on skin sections. Bar,
50 μm.
Figure 3 DMBA/TPA-induced tumor formation is delayed and
lower number of tumors is formed in TRAIL expressing mice
compared to controls. (A) DMBA and TPA treatment procedure.
Single topical application of DMBA (0.5 mg/ml) was performed,
followed by multiple applications of TPA (0.025 mg/ml), twice a
week for 35 weeks. (B) Tumor incidence; percentage of mice with at
least one tumor depending on time. (C) Total number of tumors in
wild-type versus transgenic animals. A significant difference exists
during the whole period of time of the experiment except at week
16 and week 19, as determined by Poisson distribution (D) Number
of tumors per mouse; the percentage of wild-type and transgenic
mice with different number of tumors was evaluated.
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benign lesions we could distinguish three different cate-
gories: hamartomas, trichofolliculomas and papillomas
(Figure 4A). Whereas the two first types of lesions are
benign and never transform into carcinomas, the last
represents a bona fide preneoplastic lesion, as it can
eventually evolve into a carcinoma. This classification
was confirmed by immunohistochemical analysis for
keratin 1 (K1) and a6-integrin expression, as it is well
established that K1 expression is lost whereas a6-integ-
rin expression is increased inl e s i o n sw i t hh i g hr i s ko f
transformation [35], which corresponds to our classifica-
tion (Figure 4B). When quantifying the proportion of
the different categories of lesions, we observed that wild
type animals presented half benign and half preneoplasic
lesions (Figure 4C). In contrast, less than 20% of the
lesions observed in TRAIL transgenics were preneoplas-
tic, most of them were hamartomas and trichofollicu-
loma (Figure 4C).
Activation of Wnt/b-catenin/Tcf signaling has been
reported in non-melanocytic skin tumors induced by the
two-stage carcinogenesis protocol used in the present
study [36]. We therefore analyzed the expression levels
of b-catenin in several tumors of both wild type and
transgenic mice (Figure 4D). Most notably, b-catenin
levels were lower in all the tumors extracted from
TRAIL-expressing animals relative to tumors of the
wild-type counterparts. Given the link between GSK3
and Wnt/b-catenin/Tcf signaling [37,38], we monitored
the functional status of GSK3b in the two classes of
tumors. Interestingly, the inactive form of GSK3b, which
is phosphorylated at serin 9 (GSK3bpSer9), exhibited a
significantly reduced expression level in transgenic
lesions compared to the wild type animals (Figure 4D),
suggesting that in the TRAIL overexpressing mice the
development of benign lesions with active GSK3b and,
possibly as a consequence, increased levels of b-catenin
is disfavored. Altogether, these observations support the
notion that TRAIL expression in the skin of mice partly
protects them from chemical carcinogenesis already at
the early steps when benign tumors form and progress.
Discussion
In this study, we have evaluated the effect of constitutive
TRAIL overexpression in a specific organ and its implica-
tion in tumor prevention following chemical carcinogen-
esis. Transgenic mice specifically overexpressing TRAIL
in the skin were viable and were phenotypically indistin-
guishable from their wild type littermates. Their skin
architecture was normal (data not shown); therefore,
constitutive expression of TRAIL in the basal cell layer of
the epidermis at the levels observed in the transgenic ani-
mals is not toxic and does not interfere with the normal
development and/or homeostasis of skin.
Several reports have demonstrated that TRAIL could
induce proliferation through either the ERK or the NFB
pathway [27,39,40]. In our model, we could not detect any
effect on proliferation nor any activation of either ERK or
NFB when we performed either the short DMBA/TPA
treatment or the complete treatment on the skin of
TRAIL transgenic mice compared to wild-type mice
(Figure 2 and data not shown). So in this model of trans-
genic mice, even if TRAIL overexpression does not induce
apoptosis of the normal epithelial cells, it doesn’tl e a dt o
an increase in proliferation of the cells either. It has pre-
viously been observed that in certain inflammatory condi-
tions, such as rheumatoid arthritis, TRAIL displayed a
bimodal action on the proliferation of synovial fibroblasts
[28]. The chemical carcinogenesis protocol obviously
induces inflammatory skin processes. The fact that despite
an induction of inflammation we did not observe any sig-
nificant effect of proliferation indicates that in the mouse
in vivo inflammation per se does not result in a prolifera-
tive response towards excess TRAIL. It is possible that the
effect observed in synoviocytes is cell type-specific or that,
alternatively, it requires TRAIL doses, which were not
reached in the transgenic animals.
Figure 4 TRAIL expressing mice develop less preneoplastic
lesions compared to wild-type animals. (A) Representative
images of the histologic structure of the lesions provoqued by the
treatment. DMBA/TPA treated mice develop three different types of
lesions: hamartomas, trichofolliculomas and papillomas, the two first
being benign whereas the last one is a preneoplastic lesion. Bar,
400 μm. (B) Representative immunofluorescence images of
hamartoma and papilloma lesions stained with Keratin 1 and a6
integrin. Bar, 100 μm. (C) Percentage of benign versus preneoplastic
lesions in TRAIL transgenic mice compared to wild-type mice. The
difference observed between wild-type and TRAIL transgenic lesions
is highly significant (P < 0.0001), as determined by Fisher’s exact
test. (D) Western blot analysis of wild type and transgenic tumor
samples using antibodies against two transformation markers,
inactivated GSK3 phosphorylated at Ser9 and b-catenin. Actin is
used as a loading control.
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DMBA/TPA treatment progressed into a squamous cell
carcinoma (Figure 4A) was most probably due to the
g e n e t i cb a c k g r o u n do ft h em i c ei nw h i c hw ep e r f o r m e d
the experiment. Indeed, mice from C57BL/6 background
have previously been reported to be more resistant to
tumor development and particularly to skin carcinogen-
esis, in contrast to mice having a DBA/2 genetic back-
ground which present a higher rate of tumors formation
when subjected to the same protocol [41]. However, this
resistance of benign tumors to progress to malignant
lesions provided us with the opportunity to study the
effect of high endogenous levels of TRAIL in skin on the
early step of the skin tumorigenesis. Indeed, it is gener-
ally accepted from in vitro experiments and results
obtained with xenografts in vivo that only fully trans-
formed cells are sensitive towards the apoptogenic action
of the TRAIL signaling pathways. This selectivity has
been functionally linked to the expression of oncogenes
such as Ras and Myc [42-46] but no coherent general
mechanism has evolved that would account for the
observed tumor-selectivity in a variety of experimental
systems [discussed by [25]]. In some studies an effect of
TRAIL on premalignant cells has been observed, but this
effect depended on the combination with other agents,
such as all-trans-retinyl acetate. Most notably, all-trans-
retinyl acetate sensitized premalignant adenoma cells of
APC-deficient mice to TRAIL-induced apoptosis, thus
establishing a paradigm for chemoprevention of colon
cancer by retinoic acid-TRAIL combination therapy [47].
In our model however, increased endogenous levels of
TRAIL alone were sufficient for pretransformed cells to
induce a delay in the onset of the tumorigenesis and a
statistically significant decrease in the number of these
lesions in TRAIL transgenic animals, if compared to
wild-type littermates (Figure 4C). It will be interesting
to test the effect of other drugs, such as all-trans-retinyl
acetate or even standard chemotherapy for synergistic
effects with high TRAIL levels. If confirmed using other
models of transgenic mice and other models of tumori-
genesis, this observation that TRAIL expression in a
particular cell type can play a protective role at the ear-
liest stage of tumorigenesis is of great interest. Indeed,
the present model can be readily adapted to study the
effects of high levels of endogenous TRAIL in a particu-
lar organ alone or in combination with TRAIL “sensiti-
zers” [48-50] or other cancer therapeutics. Given the
ongoing efforts to develop increasingly improved mouse
models mimicking particular human tumors, such as the
widely used MMTV-erbB2 transgenics for breast cancer,
the present mouse model constitutes a versatile preclini-
cal model to assess possible synergies between TRAIL-
based therapeutics, such as recombinant TRAIL deriva-
tives, TRAIL mimics or agonistic TRAIL receptor
antibodies, and other cancer therapeutics in a organ and
tumor type-specific manner.
List of abbreviations
TRAIL: tumor necrosis factor-related apoptosis-inducing ligand; FADD: FAS-
associated protein with death domain; DISC: death-inducing signaling
complex; DMBA: 7,12-dimethyl-benz-anthracene; TPA: 12-0-
tetradecanoylphorbol-13-acetate; SCC: squamous cell carcinoma.
Acknowledgements
This work was supported by the European Commission (contract LSHC-CT-
2005-518417 ‘EPITRON’, HEALTH-F4-2007-200767 ‘Apo-Sys’) and Ligue contre
le Cancer (équipe labellisée). V.K. is the recipient of a fellowship from La
Ligue Contre de Cancer.
We thank Jean-Marie Garnier (vector construction) and Marie-Christine Birling
(transgenesis) for help in the generation of transgenic TRAIL mice, Lydie
Venteo and Muriel Philipps for their help for the in situ hybridization and
Danilo Ceschin for statistical analyzes. We are grateful to Catherine Huck and
Judith Vallet for excellent technical assistance.
Authors’ contributions
VK participated to the conception of the study, carried out the experimental
design, performed the experiments and drafted the manuscript. SM analyzed
the histological sections and performed the classification of the lesions. She
read and approved the manuscript. HG conceived the study and
participated in its design, and helped to draft the manuscript. All authors
read and approved the final manuscript.
Conflict of interests
The authors declare that they have no competing interests.
Received: 3 January 2011 Accepted: 4 April 2011 Published: 4 April 2011
References
1. Ashkenazi A, Holland P, Eckhardt SG: Ligand-based targeting of apoptosis
in cancer: the potential of recombinant human apoptosis ligand 2/
Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/
TRAIL). J Clin Oncol 2008, 26:3621-3630.
2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK,
Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and
characterization of a new member of the TNF family that induces
apoptosis. Immunity 1995, 3:673-682.
3. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM,
Alnemri ES: Identification and molecular cloning of two novel receptors
for the cytotoxic ligand TRAIL. J Biol Chem 1997, 272:25417-25420.
4. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N,
Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al: TRAIL-R2: a novel
apoptosis-mediating receptor for TRAIL. Embo J 1997, 16:5386-5397.
5. Ashkenazi A: Targeting death and decoy receptors of the tumour-
necrosis factor superfamily. Nat Rev Cancer 2002, 2:420-430.
6. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D,
Dobles M, Hertig S, Hofmann K, Van Vlijmen H, et al: Identification of a
new murine tumor necrosis factor receptor locus that contains two
novel murine receptors for tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL). J Biol Chem 2003, 278:5444-5454.
7. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS: Molecular cloning and
functional analysis of the mouse homologue of the KILLER/DR5 tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.
Cancer Res 1999, 59:2770-2775.
8. Johnstone RW, Frew AJ, Smyth MJ: The TRAIL apoptotic pathway in
cancer onset, progression and therapy. Nat Rev Cancer 2008, 8:782-798.
9. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H,
Okumura K: Involvement of tumor necrosis factor-related apoptosis-
inducing ligand in NK cell-mediated and IFN-gamma-dependent
suppression of subcutaneous tumor growth. Cell Immunol 2001,
214:194-200.
10. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H,
Okumura K: Critical role for tumor necrosis factor-related apoptosis-
Kedinger et al. Molecular Cancer 2011, 10:34
http://www.molecular-cancer.com/content/10/1/34
Page 6 of 7inducing ligand in immune surveillance against tumor development. J
Exp Med 2002, 195:161-169.
11. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ: Increased
susceptibility to tumor initiation and metastasis in TNF-related
apoptosis-inducing ligand-deficient mice. J Immunol 2002, 168:1356-1361.
12. Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, Smyth MJ:
Cutting edge: TRAIL deficiency accelerates hematological malignancies. J
Immunol 2005, 175:5586-5590.
13. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U,
Csernok AI, Schutz G, Greiner EF, Kemp CJ, Walczak H: TRAIL-R deficiency
in mice enhances lymph node metastasis without affecting primary
tumor development. J Clin Invest 2008, 118:100-110.
14. Finnberg N, Klein-Szanto AJ, El-Deiry WS: TRAIL-R deficiency in mice
promotes susceptibility to chronic inflammation and tumorigenesis. J
Clin Invest 2008, 118:111-123.
15. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE,
Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ: Induction of tumor-
specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004,
199:437-448.
16. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N,
Yagita H, Okumura K: Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) contributes to interferon gamma-dependent natural
killer cell protection from tumor metastasis. JE x pM e d2001,
193:661-670.
17. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J,
Woodward A, Le T, et al: Tumoricidal activity of tumor necrosis factor-
related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163.
18. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C,
Chang L, McMurtrey AE, Hebert A, et al: Safety and antitumor activity of
recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
19. Georgakis GV, Li Y, Humphreys R, Andreeff M, O’Brien S, Younes M,
Carbone A, Albert V, Younes A: Activity of selective fully human agonistic
antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in
primary and cultured lymphoma cells: induction of apoptosis and
enhancement of doxorubicin- and bortezomib-induced cell death. Br J
Haematol 2005, 130:501-510.
20. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R,
Albert V, Muto M, Yoshida H, Aoki M, et al: Enhanced apoptosis and tumor
regression induced by a direct agonist antibody to tumor necrosis
factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005,
11:3126-3135.
21. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C,
Riccobene T, Johnson R, Fiscella M, Mahoney A, et al: HGS-ETR1, a fully
human TRAIL-receptor 1 monoclonal antibody, induces cell death in
multiple tumour types in vitro and in vivo. Br J Cancer 2005, 92:1430-1441.
22. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R,
Hideshima T, Anderson KC: TRAIL/Apo2L ligand selectively induces
apoptosis and overcomes drug resistance in multiple myeloma:
therapeutic applications. Blood 2001, 98:795-804.
23. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA:
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone
and in combination with chemotherapeutic agents on patients’ colon
tumors grown in SCID mice. Cancer Res 2002, 62:5800-5806.
24. Gonzalvez F, Ashkenazi A: New insights into apoptosis signaling by
Apo2L/TRAIL. Oncogene 2010, 29:4752-4765.
25. Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H: Towards novel
paradigms for cancer therapy. Oncogene 2011, 30:1-20.
26. Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M,
Maison W, Fournel S, Micheau O, et al: Multivalent DR5 peptides activate
the TRAIL death pathway and exert tumoricidal activity. Cancer Res 2010,
70:1101-1110.
27. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I: TRAIL
induced survival and proliferation in cancer cells resistant towards TRAIL-
induced apoptosis mediated by NF-kappaB. Oncogene 2003, 22:3842-3852.
28. Audo R, Combe B, Coulet B, Morel J, Hahne M: The pleiotropic effect of
TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis
patients is mediated by caspases. Cell Death Differ 2009, 16:1227-1237.
29. Kemp CJ: Multistep skin cancer in mice as a model to study the
evolution of cancer cells. Semin Cancer Biol 2005, 15:460-473.
30. Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, Metzger D,
Chambon P: Skin abnormalities generated by temporally controlled
RXRalpha mutations in mouse epidermis. Nature 2000, 407:633-636.
31. Vassar R, Rosenberg M, Ross S, Tyner A, Fuchs E: Tissue-specific and
differentiation-specific expression of a human K14 keratin gene in
transgenic mice. Proc Natl Acad Sci USA 1989, 86:1563-1567.
32. Balmain A, Ramsden M, Bowden GT, Smith J: Activation of the mouse
cellular Harvey-ras gene in chemically induced benign skin papillomas.
Nature 1984, 307:658-660.
33. Quintanilla M, Brown K, Ramsden M, Balmain A: Carcinogen-specific
mutation and amplification of Ha-ras during mouse skin carcinogenesis.
Nature 1986, 322:78-80.
34. Karen J, Wang Y, Javaherian A, Vaccariello M, Fusenig NE, Garlick JA: 12-O-
tetradecanoylphorbol-13-acetate induces clonal expansion of potentially
malignant keratinocytes in a tissue model of early neoplastic
progression. Cancer Res 1999, 59:474-481.
35. Tennenbaum T, Weiner AK, Belanger AJ, Glick AB, Hennings H, Yuspa SH:
The suprabasal expression of alpha 6 beta 4 integrin is associated with
a high risk for malignant progression in mouse skin carcinogenesis.
Cancer Res 1993, 53:4803-4810.
36. Bhatia N, Spiegelman VS: Activation of Wnt/beta-catenin/Tcf signaling in
mouse skin carcinogenesis. Mol Carcinog 2005, 42:213-221.
37. Wu D, Pan W: GSK3: a multifaceted kinase in Wnt signaling. Trends
Biochem Sci 2010, 35:161-168.
38. MacDonald BT, Tamai K, He X: Wnt/beta-catenin signaling: components,
mechanisms, and diseases. Dev Cell 2009, 17:9-26.
39. Belyanskaya LL, Ziogas A, Hopkins-Donaldson S, Kurtz S, Simon HU,
Stahel R, Zangemeister-Wittke U: TRAIL-induced survival and proliferation
of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5
expression in the absence of caspase-8. Lung Cancer 2008, 60:355-365.
40. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G:
TRAIL promotes the survival and proliferation of primary human
vascular endothelial cells by activating the Akt and ERK pathways.
Circulation 2003, 107:2250-2256.
41. Feith DJ, Shantz LM, Shoop PL, Keefer KA, Prakashagowda C, Pegg AE:
Mouse skin chemical carcinogenesis is inhibited by antizyme in
promotion-sensitive and promotion-resistant genetic backgrounds. Mol
Carcinog 2007, 46:453-465.
42. Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L,
Pintzas A: Transformation by oncogenic RAS sensitizes human colon cells
to TRAIL-induced apoptosis by up-regulating death receptor 4 and
death receptor 5 through a MEK-dependent pathway. J Biol Chem 2005,
280:22856-22867.
43. Nesterov A, Nikrad M, Johnson T, Kraft AS: Oncogenic Ras sensitizes
normal human cells to tumor necrosis factor-alpha-related apoptosis-
inducing ligand-induced apoptosis. Cancer Res 2004, 64:3922-3927.
44. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-
Deiry WS: Direct repression of FLIP expression by c-myc is a major
determinant of TRAIL sensitivity. Mol Cell Biol 2004, 24:8541-8555.
45. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY,
Dicker DT, Chiao PJ, et al: Reduction of TRAIL-induced Mcl-1 and cIAP2 by
c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-
induced death. Cancer Cell 2007, 12:66-80.
46. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC: Synthetic
lethal targeting of MYC by activation of the DR5 death receptor
pathway. Cancer Cell 2004, 5:501-512.
47. Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z, Lynch PM, Moyer MP, Wen XF,
Wu X: Chemoprevention of colorectal cancer by targeting APC-deficient
cells for apoptosis. Nature 2010, 464:1058-1061.
48. Jacquemin G, Shirley S, Micheau O: Combining naturally occurring
polyphenols with TNF-related apoptosis-inducing ligand: a promising
approach to kill resistant cancer cells? Cell Mol Life Sci 2010, 67:3115-3130.
49. Fulda S: Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr
Cancer Drug Targets 2008, 8:132-140.
50. Koschny R, Walczak H, Ganten TM: The promise of TRAIL–potential and
risks of a novel anticancer therapy. J Mol Med 2007, 85:923-935.
doi:10.1186/1476-4598-10-34
Cite this article as: Kedinger et al.: Targeted expression of tumor
necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects
mice against chemical carcinogenesis. Molecular Cancer 2011 10:34.
Kedinger et al. Molecular Cancer 2011, 10:34
http://www.molecular-cancer.com/content/10/1/34
Page 7 of 7